{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:14:41Z","timestamp":1774530881931,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Induction therapy for adults with acute lymphoblastic leukemia (ALL) is similar across essentially all regimens, comprised of vincristine, corticosteroids, and anthracyclines intensified with cyclophosphamide, asparaginase, or both. Given the lack of randomized data, to date, no regimen has emerged as standard. The authors previously evaluated cytarabine 3 g\/m<jats:sup>2<\/jats:sup> daily for 5 days with mitoxantrone 80 mg\/m<jats:sup>2<\/jats:sup> (the ALL\u20102 regimen) as a novel induction regimen. Compared with historic controls, the ALL\u20102 regimen was superior in terms of incidence of complete remission, failure with resistant disease, and activity in patients with Philadelphia chromosome (Ph)\u2010positive ALL.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors conducted a multicenter, prospective, randomized trial of the ALL\u20102 regimen compared with a standard 4\u2010drug induction (the L\u201020 regimen). Patients also received consolidation, maintenance therapy, and central nervous system prophylaxis. The trial accrued patients from August 1996 to October 2004.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The median follow\u2010up for survivors was 7 years, and the median patient age was 43 years. Responses were evaluated in 164 patients. The treatment arms were balanced in terms of pretreatment characteristics. The frequency of complete remission for the ALL\u20102 regimen versus the L\u201020 regimen was 83% versus 71% (<jats:italic>P<\/jats:italic> = .06). More patients on the L\u201020 arm failed with resistant disease (21% vs 8%; <jats:italic>P<\/jats:italic> = .02). Induction deaths were comparable at 9% (ALL\u20102) versus 7% (L\u201020). The median survival was similar; and, at 5 years, the survival rate was 33% alive on the ALL\u20102 arm versus 27% on the L\u201020.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Despite superior results of induction therapy with the ALL\u20102 regimen, this treatment did not improve long\u2010term outcomes. When coupled to the reported experience of other studies in adults with ALL, the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen. Cancer 2013. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27901","type":"journal-article","created":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T23:15:56Z","timestamp":1356131756000},"page":"1186-1194","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?"],"prefix":"10.1002","volume":"119","author":[{"given":"Nicole","family":"Lamanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard T.","family":"Heffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Seiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Maslak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Panageas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Golde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A 5\u2010drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811","volume":"85","author":"Larson RA","year":"1995","journal-title":"Blood."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.116"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402006"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037093"},{"key":"e_1_2_6_9_2","first-page":"809","article-title":"Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non\u2010Hodgkin's lymphoma for patients \u226450 years old in first complete remission: results of the EORTC ALL\u20103 trial","volume":"89","author":"Labar B","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.1988.6.6.1014","article-title":"A cause\u2010specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969","volume":"6","author":"Gaynor J","year":"1988","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.123.123"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2480"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.annonc.a057675","article-title":"Idarubicin and high\u2010dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia","volume":"1","author":"Giona F","year":"1990","journal-title":"Ann Oncol."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900101)65:1<5::AID-CNCR2820650104>3.0.CO;2-R"},{"key":"e_1_2_6_15_2","first-page":"336","article-title":"Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors","volume":"5","author":"Grant S","year":"1991","journal-title":"Leukemia."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.2002"},{"key":"e_1_2_6_17_2","first-page":"535","article-title":"Post\u2010remission cytopenias following intense induction chemotherapy for acute myeloid leukemia","volume":"8","author":"Damon LE","year":"1994","journal-title":"Leukemia."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)32504-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00232.x"},{"key":"e_1_2_6_20_2","first-page":"832","article-title":"Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia","volume":"7","author":"Weiss M","year":"1993","journal-title":"Leukemia."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.476"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V73.1.57.57","article-title":"Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy","volume":"73","author":"Hussein KK","year":"1989","journal-title":"Blood."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.11.2002"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402526"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3560"},{"key":"e_1_2_6_26_2","first-page":"1346","article-title":"Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as postremission treatment for adult patients with high\u2010risk acute lymphoblastic leukemia. Results of the PETHEMA ALL\u201093 trial","volume":"90","author":"Ribera JM","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168625"},{"key":"e_1_2_6_28_2","first-page":"85","article-title":"Current progress in the treatment of adult acute leukemia in Japan","volume":"23","author":"Ohno R","year":"1993","journal-title":"Jpn J Clin Oncol."},{"key":"e_1_2_6_29_2","unstructured":"TallmanMS(Personal Communication)."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27901","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:32:06Z","timestamp":1760290326000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27901"}},"subtitle":["Results from a prospective randomized trial"],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,3,15]]}},"alternative-id":["10.1002\/cncr.27901"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27901","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,20]]}}}